Mechanically, nivolumab (another immune checkpoint blockade) is supposed to behave similarly to pembrolizumab in GC or HCC, underlying that nivolumab could also reinvigorate the T-cell function by inhibiting the PD-1/PD-L1 signaling pathway and then target TCs; however, it is not true in the real-world studies. This evidence concerns the gene CD274 and hepatocellular carcinoma.